ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 330

Proteomic Profiling Of Synovial Fluid For The Identification Of Psoriatic Arthritis Soluble Biomarkers

Daniela Cretu1,2, Fawnda Pellett3, Rajiv Gandhi4, Eleftherios Diamandis5,6,7 and Vinod Chandran3, 1Department of Laboratory Medicine and Pathobiology, University of Toronto, Department of Laboratory Medicine and Pathobiology, Toronto, ON, Canada, 2Department of Pathology and Lab Medicine, Mount Sinai Hospital, Toronto, ON, Canada, 3Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4University Health Network, Arthritis Program, Toronto, ON, Canada, 5Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, 6Department of Pathology and Lab Medicine, Mount Sinai Hospital, Department of Pathology and Lab Medicine, Toronto, ON, Canada, 7Deaprtment of Clinical Biochemistry, University Health Network, Toronto, ON, Canada

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Proteomics and psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Psoriatic Arthritis: Clinical Aspects and Treatment I

Session Type: Abstract Submissions (ACR)

Background/Purpose:

There is a high prevalence of undiagnosed psoriatic arthritis (PsA) in patients seen in dermatology clinics. Identifying soluble biomarkers for PsA will help in screening psoriasis patients for appropriate referral to a rheumatologist as well as provide further insight into disease pathogenesis. However, identification of novel protein biomarkers in peripheral blood is difficult and unreliable. Potential PsA biomarkers are likely to originate in sites of inflammation such as inflamed joints and subsequently enter systemic circulation. We hypothesize that quantitative proteomic analysis of synovial fluid (SF) obtained from PsA patients, will generate a comprehensive list of proteins specific to PsA, facilitating the identification of potential PsA screening biomarkers.

Methods:

SF was obtained from swollen knee joints of PsA patients, and age/sex matched early osteoarthritis (OA) controls. Using strong cation exchange chromatography, followed by liquid chromatography and tandem mass spectroscopy, we extensively characterized the proteomes of pooled SF from ten PsA and ten controls. Extracted ion current (XIC) intensities were used to calculate protein abundance ratios, and were utilized to identify upregulated proteins (PsA/OA ratio>2). Selected reaction monitoring (SRM) assays were developed to relatively quantify potential markers in individual SF samples.

Results: We identified and quantified 443 proteins from both groups (False Discovery Rate <0.05). Only 45 proteins represented upregulated proteins in PsA SF (p<0.05). These were investigated using two publicly available databases (Ingenuity Pathway Analysis and DAVID Bioinformatics Resources 6.7) to identify disease relevant proteins. Gene ontology (GO) analysis classified these proteins into categories pertaining to five main biological processes: complement activation, defense response, immunoglobulin mediated response, response to wounding, and extracellular matrix remodeling, all of which are attributes of PsA. Application of subsequent filtering criteria yielded approximately 17 proteins, which served as putative PsA biomarkers. SRM validation confirmed that 13 proteins were indeed elevated in the 10 PsA SF samples, and these included positive controls, MMP3, S100A9, and CRP.

Conclusion:

We have developed and utilized a high-throughput proteomics platform using LC-MS/MS to delineate the SF proteome from PsA patients and controls with early OA. Proteins that were differentially expressed were validated using targeted mass-spectrometric assays. Using these methods we have identified several candidate PsA biomarkers. In the future, these proteins must be verified using highly specific immunoassays in serum, in order to identify their clinical utility.


Disclosure:

D. Cretu,
None;

F. Pellett,
None;

R. Gandhi,
None;

E. Diamandis,
None;

V. Chandran,

AbbVie ,

2.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/proteomic-profiling-of-synovial-fluid-for-the-identification-of-psoriatic-arthritis-soluble-biomarkers/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology